Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

DARK SECRETS: Kenvue | Rare Historical Photos

What to Expect From Kenvue’s Q2 2026 Earnings Report

Kenvue heads into its second-quarter earnings release with analysts projecting low double-digit EPS growth.

Barchart

Appeals Court Revives 500-Plus Tylenol Autism Lawsuits: What Pregnant Women Should Know About the Evidence

A federal appeals court revived 500+ Tylenol autism lawsuits on July 13, 2026. Medical societies still back acetaminophen in pregnancy. Here's what the evidence shows.

Medical Daily

US appeals court revives hundreds of lawsuits linking Tylenol to autism

IN FULL

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Judges allow lawsuit that ties Tylenol to autism to continue after it was dismissed for lack of ‘scientific evidence’

The move has revived more than 500 private lawsuits against Tylenol maker Kenvue

The Independent UK

Health officials sound the alarm over viral ‘Benadryl challenge’ after 5 kids hospitalized in San Diego

At least five kids were sent to Rady Children’s Hospital in San Diego, California, after attempting the challenge

The Independent UK

ASIA PACIFIC'S LEADING DENTAL BODY CALLS FOR A PREVENTION-FIRST SHIFT IN ORAL HEALTH, BACKED BY NEW GLOBAL EVIDENCE

SINGAPORE, May 25, 2026 /PRNewswire/ -- The Asia Pacific Dental Federation (APDF) has released The Power of Prevention: Evidence-Based Guidelines for Self-Oral Care, a landmark white paper setting out what effective daily oral care should look like and why it matters well beyond your teeth.

AAP

Ken Paxton wanted to limit forum shopping. Now lawyers say he’s improperly seeking favorable courts.

ProPublica and The Texas Tribune have identified at least 30 lawsuits filed by the attorney general over the past nine years that have a tenuous connection to the counties in which they were filed.

The Texas Tribune

Read news from The Economist, FT, and more,
with one subscription

Kenvue Stock: Is Wall Street Bullish or Bearish?

Kenvue has underperformed the broader market over the past year, and analysts remain skeptical about the stock’s prospects.

Barchart

Skip the 10-Year Bond? 3 Dividend Aristocrats to Consider Now

Three Dividend Aristocrats offer yields above the 10-year Treasury while delivering income growth and potential capital appreciation

MarketBeat

Is Marmite Still British? £50bn Sale to US Giant McCormick Sparks Concern Over Recipe Changes and Price

Unilever agrees to merge its food business, including Marmite, with US spice maker McCormick in a deal worth £50bn, raising concerns over UK jobs and prices.

International Business Times UK

Fortune Brands CEO never officially worked a day—but he’ll get $18.4 million after a massive leadership shakeup

The son-in-law of activist billionaire Nelson Peltz triggered the shakeup—and now he's getting a board seat and a say in who runs the company next

Fortune

How Is Kenvue’s Stock Performance Compared to Other Consumer Staple Stocks?

While recent performance trails the industry, Kenvue continues to retain measured analyst confidence and long-term relevance.

Barchart

Kenvue Is Headed for a Merger Vote on January 29. How Should You Play KVUE Stock Here?

KVUE stock could gain 15% this week if the potential merger with Kimberly-Clark is approved by all major stakeholders.

Barchart

Kenvue Stock: Analyst Estimates & Ratings

As Kenvue has underperformed the broader market over the past year, Wall Street analysts maintain a cautious outlook about the stock’s prospects.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Earnings Preview: What to Expect From Kenvue’s Report

Kenvue is gearing to release its fourth-quarter results shortly, and analysts expect its earnings to fall in low-double-digits.

MarketBeat

Insider Buying: Smart Money Just Spent +$100M on These 3 Stocks

Institutional insiders are placing big bets on DASH, KVUE, and KYMR. See how much is being spent on these three stocks and which investors are buying.

Barchart

Kenvue Stock: Is KVUE Underperforming the Consumer Defensive Sector?

As Kenvue has performed weaker than the consumer defensive sector over the past year, Wall Street analysts maintain a cautious outlook on the stock’s prospects.

MarketBeat

3 Smart Defensive Stocks for an Uneasy Market

Recession risks persist despite record market highs. Here are three defensive stocks—including PG, JNJ, and the DIA ETF—that can help protect your portfolio

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Court Rejects Bid To Block Kenvue's $398 Million Shareholder Payout In Tylenol Safety Dispute

On Friday, a Texas judge declined to halt an upcoming shareholder payout by Texas Attorney General Ken Paxton to restrict Kenvue Inc.'s (NYSE:KVUE) handling and marketing of Tylenol amid ongoing litigation over the product's safety for pregnant women.

The Independent UK

Despite Trump’s claims, new review by experts finds no link between Tylenol use during pregnancy and autism

Experts say pregnant women should still be advised to take Tylenol to treat pain and fever

Creative Bloq

From Meta to PepsiCo: when does a company outgrow its biggest brand?

Is PepsiCo still just 'Pepsi' to most?

The Texas Tribune

Judge denies Paxton request to block Tylenol maker from paying shareholders

Attorneys for Texas recognized their bid to block payments was an extraordinary request.

GOBankingRates

Stocks Impacted by Trump’s Comments in 2025 — From Disney to Tesla

Trump’s 2025 comments sent shockwaves through the market—see which major stocks, from Disney to Tesla, were impacted.

MarketBeat

Sticker Shock: Why Kimberly-Clark's Sell-Off Is an Overreaction

Kimberly-Clark's acquisition of Kenvue creates a global leader in health and wellness, positioning its iconic brands for accelerated long-term growth.

International Business Times UK

Kimberly-Clark Snaps Up Tylenol Maker Kenvue in £30 Billion Takeover Amid Autism Controversy

Kimberly-Clark to acquire Kenvue, owner of Tylenol, in a £40 billion deal amid controversy over the painkiller's safety concerns and declining sales.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations